Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models

Title:Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models

Volume: 13 Issue: 6

Author(s): Torsten Loop, Christian Schlensak and Ulrich Goebel

Affiliation:

Keywords: Carbon monoxide, cardiopulmonary bypass, lung, organ protection

Abstract: Although a potentially toxic gaseous molecule, carbon monoxide recently gains rising scientifically and clinical interest as its beneficial effects and mechanisms of action are defined substantially in various in vitro and in vivo experiments. Its anti-inflammatory, anti-apoptotic and anti-proliferative properties but its increasing impact concerning numerous disease models in means of protection, well describe this gas as a new and challenging therapeutic alternative.

In this review, we focus on the extensively analyzed advantageous value of pre- and postconditioning with inhaled carbon monoxide in the context of lung and kidney injury, induced by the low perfusion during and after cardiopulmonary bypass. Mechanisms like the heat shock response as well as an expanded view regarding toxicity and side effects are described broadly.

Cite this article as:

Loop Torsten, Schlensak Christian and Goebel Ulrich, Cytoprotection by Inhaled Carbon Monoxide before Cardiopulmonary Bypass in Preclinical Models, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399130